Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048104 | 0.84 | PLA2G2A (0.33) | CSF1RPLA2G2ADCTPP1TDP1 | |
| SCHEMBL3686582 | 0.83 | TDP1 (0.39) | PLA2G2AKMT2ADCTPP1TDP1 | |
| SCHEMBL12979190 | 0.83 | CSF1R (0.44) | CSF1R | |
| SCHEMBL15312704 | 0.82 | CSF1R (0.38) | CSF1RPLA2G2ADCTPP1TDP1 | |
| SCHEMBL15553240 | 0.80 | CSF1R (0.41) | CSF1RTDP1 | |
| SCHEMBL2048637 | 0.80 | CSF1R (0.45) | CSF1RDCTPP1TDP1 | |
| SCHEMBL9941533 | 0.78 | CSF1R (0.42) | CSF1RKMT2ADCTPP1 | |
| SCHEMBL2052723 | 0.77 | PLA2G2A (0.44) | CSF1RPLA2G2ADCTPP1 | |
| SCHEMBL15312696 | 0.77 | DCTPP1 (0.35) | CSF1RPLA2G2ADCTPP1TDP1 | |
| SCHEMBL2053001 | 0.77 | DCTPP1 (0.35) | CSF1RPLA2G2ADCTPP1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2516433-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-102822170-A | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| EP-2516433-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | Array Biopharma, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | CSF1R 17/4885PLA2G2A 3864/4885HDAC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.